En Carta Diagnostics, a deeptech startup focused on rapid Point-of-Care (POC) molecular diagnostics kits, has secured €1.5 million in pre-seed funding.
Led by CentraleSupélec Venture with support from high-profile business angels, this investment will enable En Carta to advance preclinical data for a prototype diagnostic kit targeting Lyme disease and scale its operations.
En Carta’s technology features a frugal cassette format using aptamers for high-precision detection of various indications, including genetic, pathogenic, and veterinary. The company’s initial focus is Lyme disease, the most prevalent vector-borne disease in the Northern Hemisphere, with 1.2 million annual cases and rising at 22.5% per year from 2000 to 2018.
Do you need investors for your startup?
CEO Guillaume Horreard highlighted the importance of accuracy, speed, and cost in the POC market, noting the critical need for rapid Lyme disease diagnosis. The funding will support the development of a diagnostic kit capable of detecting Lyme disease within minutes, as well as build a robust ecosystem and go-to-market strategy.
En Carta’s molecular diagnostic platform offers a significant improvement over current Lyme disease tests, which often fail to detect early infections due to the time required for antibody development. The company plans to present preclinical data in early 2025.
To read full article / source click here
* It is a community posted article. Please read the Full Disclaimer below
Disclaimer: This post is AI-generated. Its content does not represent the views of Xstartups. Xstartups is not liable for the accuracy or implications of the content. For any concerns or copyright issue, contact us at complaint@xstartups.co.
